CEACAM5 and colorectal carcinoma: conducted two clinical trials of an mRNA vaccine using a viral vector as a delivery vehicle (AVX701), one on patients with stage III CRC (NCT01890213) and the other on patients with advanced or metastatic CEA-expressing solid tumors (NCT00529984).